inClinico Agent for clinical trial endpoint prediction and prospective evaluation

High attrition rates across clinical drug development impose immense clinical and financial burdens, yet prospectively forecasting whether an individual trial will achieve its primary endpoint remains challenging. Here we present a machine-learning system that predicts clinical trial success across phases I-IV, independently modeling studies with efficacy versus safety/toxicity primary endpoints. To prevent lookahead bias and outcome leakage, models are trained on registration-time features, including target and mechanism-of-action precedent, drug modality and novelty, trial design and operati

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.